Patient Identification

Is ZYNTEGLO right for your patient?

ZYNTEGLO is a one-time gene therapy that expands options for patients with transfusion-dependent β-thalassaemia (TDT)
≥12 years of age who do not have a β00 genotype and who do not have an HLA-matched related donor.1 

CONSIDER TREATMENT FOR PATIENTS WHO MEET THESE CRITERIA1:

  • Diagnosed with TDT
  • Who do not have a β00 genotype
  • Patients ≥12 years of age
  • Appropriate for haematopoietic stem cell transplant (HSCT)
  • No human leukocyte antigen (HLA)–matched related haematopoietic stem cell donor available
CONTRAINDICATIONS1
  • Hypersensitivity to the active substance or to any of the excipients
  • Pregnancy and breastfeeding
  • Previous treatment with HSC gene therapy
  • Contraindications to the mobilisation agents and the myeloablative conditioning agent must be considered
Please consult the full EU Summary of Product Characteristics (EU SmPC) and the EU Abbreviated Prescribing Information (EU API) before prescribing.